OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2025
(2)
2017
(2)
2015
(2)
2021
(1)
2020
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states.
Not available
S-EPMC4661984
|
biostudies-literature
Cite
Interleukin-6 Stimulates Defective Angiogenesis.
Not available
S-EPMC4527186
|
biostudies-literature
Cite
Pathological Angiogenesis Requires Syndecan-4 for Efficient VEGFA-Induced VE-Cadherin Internalization.
Not available
S-EPMC7613699
|
biostudies-literature
Cite
Cost-Effectiveness of α2 Agonists for Intravenous Sedation in Patients With Critical Illness.
Not available
S-EPMC12090026
|
biostudies-literature
Cite
Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.
Not available
S-EPMC12090071
|
biostudies-literature
Cite
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
Not available
S-EPMC7567026
|
biostudies-literature
Cite
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Not available
S-EPMC5605509
|
biostudies-literature
Cite
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Not available
S-EPMC5605707
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets